Biosimilars can strengthen competition and reduce pharmaceutical spending. In intravitreal care, however, clinical fit, availability, contracts, operations and patient communication matter alongside price.
Biosimilars are not generics
Biological medicines are produced in living systems and are structurally more complex than chemically synthesized products. A biosimilar is therefore not a molecularly identical copy.
It must be highly similar to the reference product in structure, biological activity, efficacy, safety and immunogenicity, with no clinically meaningful differences.
Scientific comparability is assessed
The EMA has approved ranibizumab and aflibercept biosimilars for ophthalmic indications. Byooviz references Lucentis and Opuviz references Eylea; their European assessments found comparable efficacy and safety.
EMA and the Heads of Medicines Agencies consider EU-approved biosimilars scientifically interchangeable with the reference product, while national prescribing and substitution rules remain separate.
Comparable medicine does not mean identical operations
Packaging, handling, ordering, availability, lead time and contractual arrangements can differ. A switch can affect the practice system, stock management, staff identification, patient documents, billing and batch traceability.
A product change is therefore an operational change project, not only a purchasing decision.
Economic rules are differentiated
German rules require an economic choice when patients start treatment and a review of lower-cost options for existing patients when no individual medical reason prevents a switch. Discount contracts and the specific supply route matter.
A blanket statement across all intravitreal procurement models would be misleading; the product, prescription, pharmacy pathway and regional agreements must be checked.
Unit price is only one part of total economics
Availability, order quantities, expiry and waste risk, replacement procurement, administrative work and process stability affect total cost.
The lowest purchase price can become uneconomic if it causes supply interruptions, repeated changes or avoidable operational effort.
Availability is part of care quality
Intravitreal therapies often follow defined treatment intervals. A missing dose can lead to rescheduling, extra communication and a change in the treatment plan.
Manufacturers therefore need reliable supply, early information about constraints and practical implementation support within clear legal and medical boundaries.
Communication and implementation matter
Patients may ask whether a new product is equally effective or whether the switch is driven only by cost. Communication should explain the regulatory standard while making clear that the individual medical decision remains physician-led.
Before switching, practices should define eligible situations, adapt ordering and documentation, train staff and monitor medical and organizational issues after launch.
Conclusion
Biosimilars have a legitimate role in ophthalmology and can improve competition and access. Their approval is based on a comprehensive comparability assessment.
Successful use nevertheless depends on clinical suitability, reliable supply, workable processes, contracts, documentation and patient trust. Procurement optimizes price; care management optimizes the entire pathway.